Natco Pharma Limited — Anastrozole Exporter Profile
Indian Pharmaceutical Exporter · #5 for Anastrozole · $2.7M export value · DGFT Verified
Natco Pharma Limited is the #5 Indian exporter of Anastrozole with $2.7M in export value and 68 verified shipments. Natco Pharma Limited holds a 2.4% market share in Anastrozole exports across 10 countries. The company exports 17 pharmaceutical products worth $36.0M across 6 therapeutic categories.
Natco Pharma Limited — Anastrozole Export Profile: Buyers & Destinations
Where Does Natco Pharma Limited Export Anastrozole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $409.2K | 23 | 42.3% |
| UNITED KINGDOM | $204.1K | 6 | 21.1% |
| UNITED STATES | $200.0K | 4 | 20.7% |
| GERMANY | $121.1K | 9 | 12.5% |
| PHILIPPINES | $16.3K | 3 | 1.7% |
| INDONESIA | $7.4K | 1 | 0.8% |
| PARAGUAY | $4.4K | 1 | 0.5% |
| TANZANIA | $3.2K | 1 | 0.3% |
| SINGAPORE | $2.3K | 3 | 0.2% |
| MALTA | $17 | 17 | 0.0% |
Natco Pharma Limited exports Anastrozole to 10 countries. The largest destination is CANADA accounting for 42.3% of Natco Pharma Limited's Anastrozole shipments, followed by UNITED KINGDOM (21.1%) and UNITED STATES (20.7%). These destinations reflect Natco Pharma Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Anastrozole from Natco Pharma Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MARCAN PHARMACEUTICALS INC | CANADA | $240.2K | 11 |
| BRECKENRIDGE PHARMACEUTICAL INC | UNITED STATES | $150.0K | 3 |
| LEXON UK LIMITED | UNITED KINGDOM | $150.0K | 3 |
| MARCAN PHARMACEUTICALS INC, | CANADA | $122.0K | 4 |
| LEXON (UK) LIMITED | UNITED KINGDOM | $54.1K | 3 |
| XXECKXXRIDXX PHXXMACXXTICXX IXX | UNITED STATES | $50.0K | 1 |
| HEUMANN PHARMA GMBH & CO. | GERMANY | $41.1K | 3 |
| HEUNET PHARMA GMBH | GERMANY | $33.4K | 2 |
| NATCO PHARMA (CANADA) INC | CANADA | $28.5K | 4 |
| HEUNET PHARMA GMBH AND CO GENERICA KG | GERMANY | $24.4K | 1 |
Natco Pharma Limited supplies Anastrozole to 21 buyers globally. The largest buyer is MARCAN PHARMACEUTICALS INC (CANADA), followed by BRECKENRIDGE PHARMACEUTICAL INC (UNITED STATES) and LEXON UK LIMITED (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Anastrozole Export Value and How Much Does Natco Pharma Limited Contribute?
India exported $25.8M worth of Anastrozole through 2,238 shipments from 158 suppliers to 99 countries, serving 387 buyers globally. Natco Pharma Limited contributes $2.7M to this total, accounting for 2.4% of India's Anastrozole exports. Natco Pharma Limited ships Anastrozole to 10 countries through 21 buyers.
What Is the Average Shipment Value for Natco Pharma Limited's Anastrozole Exports?
Natco Pharma Limited's average Anastrozole shipment value is $39.5K per consignment, based on 68 shipments totaling $2.7M. The largest destination is CANADA (42.3% of Natco Pharma Limited's Anastrozole exports).
How Does Natco Pharma Limited Compare to Other Indian Anastrozole Exporters?
Natco Pharma Limited ranks #5 among 158 Indian Anastrozole exporters with a 2.4% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($10.4M), ZYDUS LIFESCIENCES LIMITED ($3.6M), EUGIA PHARMA SPECIALITIES LIMITED ($3.5M). Natco Pharma Limited processed 68 shipments to 10 destination countries.
What Anastrozole Formulations Does Natco Pharma Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ANASTROZOLE TABLETS USP 1MG - BT | $100.0K | 2 |
| ANASTROZOLE 1MG TABLETS 28S (QTY.108160X28'S=3028480 NOS)(RODTEP ENTRY NO.10112)(OTHER REF CI NO.123277)NOS | $54.1K | 3 |
| ANASTROZOLE TABLETS 1MG 30'S (15200X30'S | $50.0K | 1 |
| ANASTROZOLE TABLET USP 1 MG BT90'S | $50.0K | 1 |
| ANASTROZOLE TABLETS 1MG 30'S 17230 X 30'S PACK OTHER REF CI NO:123169 RODTEP ENTRY NO: 10112 | $50.0K | 1 |
| ANASTROZOLE TABLETS USP, 1MG BT 30'S | $50.0K | 1 |
| ANASTROZOLE 1MG TABLETS 30'S (12570X30'S)(APPENDIX 4R, RODTEP ENTRY NO:10112)(OTHER REFERENCE(S)CI NO:123279) | $50.0K | 1 |
| ANASTROZOLE 1MG TABLETS 28'S (QTY.107855X28'S=3019940 NOS)(RODTEP ENTRY NO.10112)(OUR REF CI NO.124053) | $50.0K | 1 |
| ANASTROZOLE 1MG TABLETS 28'S (QTY.166570X28'S=4663960 NOS)(RODTEP ENTRY NO.10112)(OUR REF CI NO.125006) | $50.0K | 1 |
| ANASTROZOLE 1MG TABLETS 28'S (QTY.165104X28'S=4622912 NOS)(RODTEP ENTRY NO.10112)(OUR REF CI NO.125005) | $50.0K | 1 |
Natco Pharma Limited exports 60 distinct Anastrozole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ANASTROZOLE TABLETS USP 1MG - BT with 2 shipments worth $100.0K.
Regulatory Requirements: Exporting Anastrozole to Key Markets
What Natco Pharma Limited must comply with to export Anastrozole to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Natco Pharma Limited Compare to Nearest Anastrozole Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | EUGIA PHARMA SPECIALITIES LIMITED | $3.5M | 116 | 6 | $30.4K |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $3.1M | 70 | 5 | $44.9K |
| 5 | NATCO PHARMA LIMITED ★ | $2.7M | 68 | 10 | $39.5K |
| 6 | JODAS EXPOIM PRIVATE LIMITED | $1.2M | 24 | 3 | $50.0K |
| 7 | CADILA HEALTHCARE LTD | $450.0K | 9 | 1 | $50.0K |
Natco Pharma Limited ranks #5 among 158 Indian Anastrozole exporters. Average shipment value of $39.5K compared to the market average of $163.1K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Anastrozole Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 465 | 20.8% |
| SAHAR AIR | 391 | 17.5% |
| DELHI AIR CARGO ACC (INDEL4) | 280 | 12.5% |
| DELHI AIR | 167 | 7.5% |
| MUNDRA SEA | 90 | 4.0% |
| Bombay Air | 86 | 3.8% |
| HYDERABAD AIR | 75 | 3.4% |
| MUNDRA SEA (INMUN1) | 70 | 3.1% |
What Other Advanced Oncology Products Does Natco Pharma Limited Export?
Natco Pharma Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Natco Pharma Limited's Anastrozole Exports
Natco's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The U.S. administration's imposition of tariffs on imports from various countries, including India, has raised concerns about the competitiveness of Indian generics in the U.S. market. These tariffs could potentially erode profit margins and affect pricing strategies. (apnews.com)
Conversely, the European Union's stringent regulatory changes, such as the Falsified Medicines Directive, have heightened compliance requirements for exporters. While these regulations aim to ensure product authenticity and safety, they also necessitate significant investments in serialization and traceability systems. For companies like Natco, adhering to these standards is crucial for maintaining access to the lucrative EU market.
Natco Pharma Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing intensified scrutiny regarding quality and compliance. The U.S. Food and Drug Administration (FDA) has increased inspections of Indian manufacturing facilities, emphasizing adherence to Good Manufacturing Practices (GMP). Non-compliance can lead to warning letters, import alerts, or even bans, posing significant risks to exporters. (fact.net.in)
Natco's commitment to quality is evident in its proactive measures to meet international standards. The company's recent product approvals and successful market entries suggest a robust compliance framework. However, continuous vigilance and investment in quality systems are imperative to navigate the evolving regulatory landscape and to sustain export growth.
About Natco Pharma Limited
Natco Pharma Limited exports 17 products worth $36.0M. Beyond Anastrozole, top products include Everolimus, Oseltamivir, Apixaban, Ondansetron, Imatinib. View the complete Natco Pharma Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Anastrozole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Anastrozole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Natco Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 68 individual customs records matching Natco Pharma Limited exporting Anastrozole, covering 60 formulations to 10 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 99+ countries, 387+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Anastrozole Export Data from Natco Pharma Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Natco Pharma Limited's Anastrozole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Natco Pharma Limited
Full Company Profile →
17 products · $36.0M total trade · 6 categories
Anastrozole Stats
Company Overview
Top Products by Natco Pharma Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Natco Pharma Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Anastrozole. For current shipment-level data, contact TransData Nexus.